Log in

PDL BioPharma Stock Forecast, Price & News

+0.07 (+3.20 %)
(As of 10/23/2020 12:00 AM ET)
Today's Range
Now: $2.26
50-Day Range
MA: $2.90
52-Week Range
Now: $2.26
Volume972,776 shs
Average Volume895,174 shs
Market Capitalization$257.59 million
P/E RatioN/A
Dividend YieldN/A
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.
Read More
PDL BioPharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 1.6Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.97 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:PDLI



Sales & Book Value

Annual Sales$54.76 million
Cash Flow$0.46 per share
Book Value$5.20 per share


Net Income$-70,410,000.00


Market Cap$257.59 million
Next Earnings Date11/4/2020 (Estimated)
+0.07 (+3.20 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PDLI News and Ratings via Email

Sign-up to receive the latest news and ratings for PDLI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

PDL BioPharma (NASDAQ:PDLI) Frequently Asked Questions

How has PDL BioPharma's stock been impacted by Coronavirus?

PDL BioPharma's stock was trading at $3.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PDLI shares have decreased by 26.4% and is now trading at $2.26.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of PDL BioPharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PDL BioPharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for PDL BioPharma

When is PDL BioPharma's next earnings date?

PDL BioPharma is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for PDL BioPharma

How were PDL BioPharma's earnings last quarter?

PDL BioPharma, Inc. (NASDAQ:PDLI) released its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.10 by $0.53. The biotechnology company had revenue of $5.21 million for the quarter.
View PDL BioPharma's earnings history

How often does PDL BioPharma pay dividends? What is the dividend yield for PDL BioPharma?

PDL BioPharma announced a quarterly dividend on Thursday, September 10th. Investors of record on Tuesday, September 22nd will be given a dividend of $0.076 per share on Thursday, October 1st. This represents a $0.30 dividend on an annualized basis and a yield of 13.45%. The ex-dividend date is Monday, September 21st. This is a boost from PDL BioPharma's previous quarterly dividend of $0.05.
View PDL BioPharma's dividend history

What price target have analysts set for PDLI?

1 brokers have issued 1-year target prices for PDL BioPharma's stock. Their forecasts range from $3.00 to $3.00. On average, they expect PDL BioPharma's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 32.7% from the stock's current price.
View analysts' price targets for PDL BioPharma

Are investors shorting PDL BioPharma?

PDL BioPharma saw a decrease in short interest in September. As of September 30th, there was short interest totaling 9,850,000 shares, a decrease of 24.8% from the September 15th total of 13,100,000 shares. Based on an average daily trading volume, of 1,100,000 shares, the days-to-cover ratio is presently 9.0 days. Approximately 9.0% of the shares of the stock are sold short.
View PDL BioPharma's Short Interest

Who are some of PDL BioPharma's key competitors?

What other stocks do shareholders of PDL BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PDL BioPharma investors own include AT&T (T), Opko Health (OPK), Canopy Growth (CGC), Advanced Micro Devices (AMD), Novavax (NVAX), General Electric (GE), Teva Pharmaceutical Industries (TEVA), Bank of America (BAC), Bausch Health Companies (BHC) and Cara Therapeutics (CARA).

Who are PDL BioPharma's key executives?

PDL BioPharma's management team includes the following people:
  • Mr. Dominique P. Monnet, CEO, Pres & Director (Age 59, Pay $1.2M)
  • Mr. Edward A. Imbrogno CPA, VP, CFO & Chief Accounting Officer (Age 55, Pay $564.14k)
  • Mr. Christopher L. Stone, VP, Gen. Counsel & Sec. (Age 56, Pay $1.15M)
  • Mr. Nathan Kryszak, Deputy Gen. Counsel & Assistant Sec.

What is PDL BioPharma's stock symbol?

PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."

Who are PDL BioPharma's major shareholders?

PDL BioPharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Bellecapital International Ltd. (0.09%), Deltec Asset Management LLC (0.04%) and Nisa Investment Advisors LLC (0.01%).
View institutional ownership trends for PDL BioPharma

Which institutional investors are buying PDL BioPharma stock?

PDLI stock was purchased by a variety of institutional investors in the last quarter, including Bellecapital International Ltd., Deltec Asset Management LLC, and Nisa Investment Advisors LLC.
View insider buying and selling activity for PDL BioPharma

How do I buy shares of PDL BioPharma?

Shares of PDLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PDL BioPharma's stock price today?

One share of PDLI stock can currently be purchased for approximately $2.26.

How big of a company is PDL BioPharma?

PDL BioPharma has a market capitalization of $257.59 million and generates $54.76 million in revenue each year. The biotechnology company earns $-70,410,000.00 in net income (profit) each year or $0.28 on an earnings per share basis. PDL BioPharma employs 109 workers across the globe.

What is PDL BioPharma's official website?

The official website for PDL BioPharma is www.pdl.com.

How can I contact PDL BioPharma?

PDL BioPharma's mailing address is 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV, 89451. The biotechnology company can be reached via phone at 775-832-8500 or via email at [email protected]

This page was last updated on 10/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.